Collecting tumor samples from triple-negative breast cancer patients to explore new treatments and biomarkers.
Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment
Centre Francois Baclesse · NCT05404321
This study is collecting tumor samples from people with triple-negative breast cancer to see if new treatments and markers can help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 163 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Francois Baclesse (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Caen) |
| Trial ID | NCT05404321 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a collection of ex vivo tumor organoids from patients with triple-negative breast cancer. By utilizing advanced 3D cell culture techniques, the study will create organoid models that closely mimic the original tumors, allowing for the evaluation of innovative therapies and the identification of predictive biomarkers for treatment response. The organoids will be derived from patients undergoing neoadjuvant chemotherapy and will be analyzed for their growth and response to various treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with early-stage triple-negative breast cancer who require clips placed before neoadjuvant chemotherapy.
Not a fit: Patients who are pregnant or have a history of clinically active malignancy in the last 5 years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment options and personalized therapies for patients with triple-negative breast cancer.
How similar studies have performed: While the use of organoids in cancer research is gaining traction, this specific approach to triple-negative breast cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age * Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy * Patient affiliated to a social security system * Proficiency in French language, * Patient having signed the consent to participate in the study. Exclusion Criteria: * Pregnant women * Persons deprived of liberty or under guardianship (including curatorship) * History of any other clinically active malignancy in the last 5 years prior to inclusion
Where this trial is running
Caen
- Centre François Baclesse — Caen, France (RECRUITING)
Study contacts
- Study coordinator: George EMILE, MD
- Email: g.emile@baclesse.unicancer.fr
- Phone: +33 2 31 45 50 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Triple Negative Breast Cancer, Organoid